SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients.

[1]  F. Esteva.  Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. , 2004, The oncologist.

[2]  K. O'Byrne,et al.  SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  S. Franco,et al.  Clinical Experience with Trastuzumab (Herceptin) , 2003, The breast journal.

[4]  A. Dalgleish,et al.  A randomized phase II trial of SRL172 (Mycobacterium vaccae) ± low-dose interleukin-2 in the treatment of metastatic malignant melanoma , 2003, Melanoma research.

[5]  D. Yee,et al.  Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  C. Arteaga,et al.  Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.

[7]  A. Padhani,et al.  Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma , 2002, British Journal of Cancer.

[8]  L. Assersohn,et al.  A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

[9]  D. Slamon,et al.  Trastuzumab and chemotherapeutics: drug interactions and synergies. , 2000, Seminars in oncology.

[10]  C. Ryan,et al.  A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma , 2000, British Journal of Cancer.

[11]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[12]  Jeffrey S. Miller,et al.  Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. , 1999, Experimental hematology.

[13]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[14]  B. Baban,et al.  Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[16]  M. Groves,et al.  Formulation and Biological Activity of Antineoplastic Proteoglycans Derived from Mycobacterium vaccae in Chitosan Nanoparticles , 1999, The Journal of pharmacy and pharmacology.

[17]  B. Baban,et al.  Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). , 1998, British journal of urology.

[18]  G. Rook,et al.  Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae , 1998, Immunology.

[19]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[20]  J. Watson,et al.  Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis , 1997, Infection and immunity.

[21]  Yosef Yarden,et al.  A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.

[22]  M. Clerici,et al.  The tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. , 1996, Journal of the National Cancer Institute.

[23]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[24]  G. Rook,et al.  Tuberculosis and cancer: parallels in host responses and therapeutic approaches? , 1995, The Lancet.

[25]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[26]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.